AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10764173
Drug: Peroperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroperative morphine titration (3 mg i.v. every 5 or 10 min until respiratory rate decreased)
Trial: 10764173
Drug: Postoperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative morphine administration in PACU
Trial: 10764173
Drug: Peroperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroperative morphine titration
Trial: 6619041
Drug: Mezlocillin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (18 g/day)
Trial: 6619041
Drug: Carbenicillin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin (18 g/day)
Trial: 28051800
Drug: Rifaximin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1,200 mg/day)
Trial: 25079593
Drug: Endomyocardial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endomyocardial injection of BM cells (100 million, n=19)
Trial: 21990263
Drug: Acetylcholine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (5-20 µg/min)
Trial: 19549739
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (22.5 mg as Nitro-Bid)
Trial: 11749950
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs), administered twice daily for 12 weeks or longer
Trial: 2850891
Drug: Trimethoprim-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment 4-times a day for 7 days
Trial: 2850891
Drug: Chloramphenicol ophthalmic
RxNorm normalized name: chloramphenicol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ophthalmic ointment 4-times a day for 7 days
Trial: 26307903
Drug: Thrice-daily human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily human regular U-500 insulin (U-500R)
Trial: 26307903
Drug: Twice-daily human
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily human regular U-500 insulin (U-500R)
Trial: 26307903
Drug: Thrice-daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily and twice-daily human regular U-500 insulin (U-500R)
Trial: 21665223
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (400 mg) or ground dried fish (529 ± 109 mg)
Trial: 6306060
Drug: Nabilone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (2 mg)
Trial: 3002167
Drug: Prochlorperazine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (15 mg)
Trial: 28032481
Drug: SER100 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER100 (10 mg)
Trial: 26301645
Drug: NAC (N-acetylcysteine)
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC (N-acetylcysteine) with sustained sodium chloride regime (1 mL/kg/h for 12 hours before, during, and 6 hours after the procedure) and oral NAC at 1.2 g bid for 3 days (n = 185)
Trial: 26301645
Drug: SOB (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOB (sodium bicarbonate) with abbreviated SOB regime (3 mL/kg/h 1 hour before the procedure, and 1 mL/kg/h during and 6 hours after the procedure) (n = 182)
Trial: 26301645
Drug: COM (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COM (combination of abbreviated SOB regime and oral NAC) (n = 181)
Trial: 19508995
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of BMMNC (n = 41)
Trial: 16396971
Drug: Intravenous darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous darbepoetin alfa (32.1 microg/week)
Trial: 16396971
Drug: Subcutaneous darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous darbepoetin alfa (34.1 microg/week)
Trial: 14607958
Drug: C5a receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C5a receptor antagonist (10 mg/kg/day peroral, 0.3 mg/kg/day s.c.)
Trial: 14607958
Drug: Prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1 mg/kg/day s.c.)
Trial: 14607958
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg i.v.)
Trial: 14607958
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of C5a antagonist and prednisolone
Trial: 14607958
Drug: Colitis control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colitis control (drug-free)
Trial: 8930228
Drug: 1500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/d CNA (ENDURACIN) for 2 months
Trial: 8930228
Drug: 2000 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/d CNA for 2 months
Trial: 1357453
Drug: Famotidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (10 mg bolus followed by 3.2 mg/h intravenously for 72 hours)
Trial: 31086947
Drug: Control (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hepatitis E vaccine)
Trial: 29749688
Drug: Constraint‐induced aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced aphasia therapy (CIAT)
Trial: 29749688
Drug: Stimulation aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation aphasia therapy (SAT)
Trial: 22057730
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of water (control)
Trial: 16052584
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy (etanercept and infliximab)
Trial: 12444542
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg daily, increased to 10 mg daily if necessary after 6 weeks)
Trial: 12444542
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 mg daily, increased to 60 mg daily if necessary after 6 weeks)
Trial: 7020194
Drug: Irradiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation of the larynx and all neck nodes (T+N), tumor dose 5130 rad/6‐7 weeks
Trial: 7020194
Drug: Irradiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation of the laryngeal portals only (T), tumor dose 5130 rad/5 weeks
Trial: 26540987
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapies and autologous BM-MNC transplantation
Trial: 10547405
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapies
Trial: 21170641
Drug: Calcium-fortified ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-fortified ice cream containing 96, 244, 459 or 676 mg calcium daily for 28 days
Trial: 21170641
Drug: Calcium-fortified ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-fortified ice cream (244 mg calcium preparation)
Trial: 10509847
Drug: Cefdinir 14
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 14 mg/kg QD
Trial: 11144398
Drug: Cefdinir 7
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 7 mg/kg BID
Trial: 10509847
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 10 mg/kg 4 times daily
Trial: 8568623
Drug: Sublingual oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual oxytocin (400 int. units / 684 micrograms)
Trial: 8568623
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (1 int. unit / 1.71 micrograms)
Trial: 7006790
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with 5-FU (9 mg/kg intravenously for five consecutive days) and CCNU (70 mg/m2 orally on the first day of each course).
Trial: 7006790
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (control group).
Trial: 7006790
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with 5-FU and CCNU.
Trial: 28506979
Drug: Ezetimibe added
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe added to simvastatin therapy
Trial: 21355446
Drug: New pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pharmaceutical equivalent tablet formulation containing 300 mg of TDF
Trial: 9893184
Drug: Short-term immunotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term immunotherapy with 7 preseasonal injections of molecular standardized allergens from grass and rye pollen
Trial: 8751095
Drug: Buffer solution
RxNorm normalized name: Buffer Solution, pH 5.00, Reference Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer solution (control)
Trial: 7029275
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of vitamin E per kilogram of body weight per day
Trial: 31011868
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri 4659 (L. reuteri) plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus L. reuteri/bid for 10 days
Trial: 31011868
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus placebo/bid for 10 days
Trial: 29078109
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health checklist intervention
Trial: 11919404
Drug: Standard Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Heparin
Trial: 10607234
Drug: Combined prednisolone/interferon‐alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined prednisolone/interferon‐alpha2b (IFN‐alpha2b) therapy
Trial: 10607234
Drug: Interferon‐alpha2b (IFN‐alpha2b)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alpha2b (IFN‐alpha2b) therapy
Trial: 7642417
Drug: Simultaneous chemoradiation
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemoradiation therapy (cisplatin 30 mg/m2 for 3 days, etoposid 80 mg/m2 for 3 days, 5-fluorouracil 900 mg/m2 for 4 days, radiation therapy 2 Gy twice a day for 5 days)
Trial: 7642417
Drug: Simultaneous chemoradiation
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemoradiation therapy
Trial: 25241107
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (6-g bolus followed by 2 g/hour infusion for up to 12 hours)
Trial: 19264239
Drug: <2-h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <2-h infusion of eptifibatide
Trial: 19264239
Drug: 18-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18-h infusion of eptifibatide
Trial: 17546553
Drug: Lepirudin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming)
Trial: 17546553
Drug: Heparin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (400 U/kg b. w. bolus with protamine reversal)
Trial: 15483780
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.8 g/kg/day) for diabetic patients
Trial: 15483780
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6 g/kg/day) for nondiabetic patients
Trial: 11280671
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 microg/puff) with low inspiratory flow rate (0.6 l/s)
Trial: 11280671
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 microg/puff) with high inspiratory flow rate (1.2 l/s)
Trial: 9470565
Drug: Tartar-control dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartar-control dentifrice (containing tetrapotassium pyrophosphate, PEG‐6, disodium pyrophosphate, and tetrasodium pyrosulphate in a 5.0% soluble pyrophosphate formulation)
Trial: 7930696
Drug: CD4-PE40 infusions
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4-PE40 infusions
Trial: 3150630
Drug: Thymostimulin (TST)
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TST) plus chemotherapy
Trial: 27573562
Drug: Pictilisib (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pictilisib (260 mg daily on days 1-5 every week) with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Trial: 27573562
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle)
Trial: 26571324
Drug: Thermal balancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal balancing therapy using a Therapeutic Device for 6 months
Trial: 20373114
Drug: Somatostatin (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (high-dose infused over 12 h)
Trial: 20373114
Drug: Somatostatin (pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (pancreatic duct injection)
Trial: 20373114
Drug: Octreotide (high-dose)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (high-dose)
Trial: 20373114
Drug: Octreotide (pancreatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (pancreatic duct injection)
Trial: 18442357
Drug: Isoflavone-intact soya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-intact soya protein (active treatment)
Trial: 15722803
Drug: Cognitive-behavioral intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral intervention and preventive physical therapy
Trial: 15722803
Drug: Minimal Treatment
RxNorm normalized name: Minimally modified low density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Treatment Group (examination, reassurance, and activity advice)
Trial: 12666111
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 10 gm daily
Trial: 8558219
Drug: CMFVP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFVP (cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 intravenously weekly for 1 year, fluorouracil 400 mg/m2 intravenously weekly for 1 year, vincristine 0.625 mg/m2 intravenously weekly for the first 10 weeks, and prednisone weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2)
Trial: 6650108
Drug: Brief courses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief courses of antibiotics active against major contaminating bacterial pathogens given prior to surgery
Trial: 6650108
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of antibiotics after surgery
Trial: 29324539
Drug: Nurse-led telephone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led telephone intervention (Optimal Personalised Care After Treatment-Gynaecological)
Trial: 17414467
Drug: Accelerated multimodality
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated multimodality treatment program including a 12-day induction course of radiation (1.5 Gy twice daily to a total of 30 Gy) concurrent with continuous intravenous infusions of cisplatin (20 mg/m2 per day) and 5-fluorouracil (1000 mg/m2 per day), followed by surgery and a second course of chemoradiotherapy.
Trial: 17414467
Drug: Accelerated multimodality
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated multimodality treatment program
Trial: 15114104
Drug: Both HTK
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HTK and UW solutions
Trial: 11599601
Drug: Marinol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marinol (15 mg)
Trial: 11599601
Drug: Smoked THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked THC (16.88 mg) in a placebo marijuana cigarette
Trial: 10984320
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone substitution therapy
Trial: 8055724
Drug: Narcotics (intramuscular/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotics (intramuscular/oral analgesics) after overnight hospital stay
Trial: 8055724
Drug: SQMP (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQMP (subcutaneous infusion of morphine sulfate via home infusion pump)
Trial: 233889
Drug: Saturated free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated free fatty acids (C3 to C18) applied daily under occlusive patch tests
Trial: 233889
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (C18 unsaturated fatty acid) applied daily under occlusive patch tests
Trial: 30153126
Drug: Subcutaneous local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous local anesthesia (group S)
Trial: 24672620
Drug: Compressor-administered defibrillation
RxNorm normalized name: Ulva compressa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compressor-administered defibrillation
Trial: 24672620
Drug: Facilitator-administered defibrillation
RxNorm normalized name: sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facilitator-administered defibrillation
Trial: 22959807
Drug: Temoporfin mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm A: 0.15 mg/kg Foscan; 96 h drug-light interval
Trial: 22959807
Drug: Temoporfin mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm B: 0.10 mg/kg; 48 h drug-light interval
Trial: 22959807
Drug: Temoporfin mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temoporfin mediated photodynamic therapy (PDT) - Arm C: 0.075 mg/kg; 24 h drug-light interval
Trial: 22959807
Drug: Temoporfin mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temoporfin mediated photodynamic therapy (PDT) - All arms
Trial: 19374210
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of hyperbaric S75:R25 bupivacaine (10 mg)
Trial: 19374210
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of hyperbaric S75:R25 bupivacaine (12 mg)
Trial: 19374210
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of hyperbaric S75:R25 bupivacaine (16 mg)
Trial: 19374210
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of hyperbaric S75:R25 bupivacaine (20 mg)
Trial: 8582461
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg at 10:00 h
Trial: 8582461
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg at 22:00 h
Trial: 2206038
Drug: Fructans (FAs)
RxNorm normalized name: fructone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructans (FAs) isolated from Jerusalem artichokes, 20 g dose
Trial: 2206038
Drug: Fructans (FAs)
RxNorm normalized name: fructone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructans (FAs) added to a wheat-starch meal, 10 g FA with 50 g wheat-starch
Trial: 209710
Drug: Four-drug combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug combination chemotherapy (vincristine, CCNU, cyclophosphamide, methotrexate)
Trial: 209710
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination chemotherapy (CCNU, cyclophosphamide, methotrexate)